

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): February 9, 2023

Clovis Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35347
(Commission
File Number)

90-0475355
(I.R.S. Employer
Identification No.)

5500 Flatiron Parkway, Suite 100
Boulder, Colorado
(Address of principal executive offices)

80301
(Zip Code)

Registrant's telephone number, including area code: (303) 625-5000

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class	Trading symbol(s) ⁽¹⁾	Name of each exchange on which registered
Common Stock par Value \$0.001 per Share	CLVSQ	N/A

- ⁽¹⁾ On December 21, 2022, our common stock was suspended from trading on the NASDAQ Global Select Market (“NASDAQ”). On December 21, 2022, our common stock began trading on the OTC Pink Marketplace maintained by the OTC Markets Group, Inc. under the symbol “CLVSQ.” On December 29, 2022, NASDAQ filed a Form 25 delisting our common stock from trading on NASDAQ, which delisting became effective at the opening of the trading session on January 9, 2023. In accordance with Rule 12d2-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the de-registration of our common stock under Section 12(b) of the Exchange Act will become effective 90 days from the date of the Form 25 filing.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 7.01 Regulation FD Disclosure.

As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the “Company”) and certain of its subsidiaries (such subsidiaries being Clovis Oncology Ireland Limited (“Clovis Ireland”) and Clovis Oncology UK Limited (“Clovis UK”) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”).

On February 9, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended December 31, 2022, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference.

The Company expects to file future Monthly Operating Reports and other documents with the Court while the Cases remain pending. The filing of such reports and other documents may not be accompanied by a Form 8-K filing. The reports and other documents will also be available for review free of charge at <https://cases.ra.kroll.com/Clovis/>. Investors should review this website for additional information regarding the Company and the Cases.

Cautionary Note Regarding the Monthly Operating Reports

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Reports, which were not prepared for the purpose of providing the basis for an investment decision relating to the Company's securities. The Monthly Operating Reports are limited in scope and have been prepared solely for the purpose of complying with requirements of the Court. The Monthly Operating Reports were not reviewed by independent accountants, are in a format prescribed by applicable bankruptcy laws, and are subject to future adjustment. The financial information in the Monthly Operating Reports are not prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and, therefore, may exclude items required by GAAP, such as certain reclassifications, eliminations, accruals, valuations and disclosures. The Monthly Operating Reports also relate to periods that are different from the historical periods required in the Company's reports pursuant to the Securities Act of 1933, as amended, or the Exchange Act.

Limitation on Incorporation by Reference

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 is being furnished for informational purposes only and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this current report (including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 attached hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.

Item 8.01 Other Events.

In connection with the Cases, the Debtors have obtained customary relief from the Court to transition into Chapter 11 without material disruption to their operations, including paying employee wages and benefits, maintaining relationships with vendors and suppliers in order to continue to supply Rubraca to patients, continuing its cash management system in the ordinary course of business, manage ongoing clinical trials and maintain regulatory approvals.

The Debtors have obtained \$45 million of new money "debtor-in possession" (DIP) financing and the consensual use of cash collateral, proceeds of which, subject to the DIP Budget and certain other financing and operating covenants set forth in the DIP Credit Agreement and the DIP Order, may be used by the Debtors for their working capital needs, including maintaining their operations and funding the costs of the administration of the Cases.

The commencement of the Cases has not had a material impact on the Company's ongoing sponsored clinical trials; however, marketing and promotion of Rubraca have been significantly curtailed as a result of more limited resources within the DIP Budget and continuing management of expenses, including the termination of a significant portion of the Company's commercial sales organization in the US and almost entirely in Europe, which has and will continue to impact revenues. As of February 9, 2023, the Company has 140 employees. In order to continue to compensate and incentivize employees to implement the Company's strategy in bankruptcy for the benefit of stakeholders, including running a successful sales process and a transition of the Company's businesses to interested purchasers, with the approval of the Court, the Company has implemented a Key Employee Retention Program (KERP) for certain non-insiders and will seek Court approval to implement a Key Employee Incentive Plan (KEIP) for certain insiders, including the Company's executive management team.

The regulatory landscape for Rubraca remains uncertain. The Company's prior submission of an sNDA to the FDA and a Type II variation to EMA for a first-line maintenance treatment indication of Rubraca for women with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy are still pending. The sNDA was accepted for a standard review with a PDUFA date of June 25, 2023. The Day-74 letter from the FDA, which notifies an applicant of issues identified during the filing review phase and was received by the Company on November 4, 2022, reiterated that the submitted OS data from the ATHENA-MONO trial are immature and expressed the view that the current trends of certain OS HR estimates indicate that there may be potential harm for patients in certain sub-groups. The OS data submitted in the sNDA were immature at 15.8% (HRD) and 24.7% (ITT) with no statistically significant differences between rucaparib and control. The Company's current estimates suggest the OS data may reach 50% maturity in the first quarter of 2024 and 70% maturity in the fourth quarter of 2026. Based on

standard review timelines, FDA may have held its internal Mid-Cycle Meeting for the pending sNDA, and the Company awaits receipt of the Mid-Cycle Communication, which would be expected to provide an update on the review status of the application. Additionally, as previously disclosed, the Company concluded discussions with the FDA on a revised label to limit Rubraca's use in the second-line ovarian cancer maintenance indication to the tBRCA mutation patient population only, and the revised label was approved on December 21, 2022. With respect to the Type II variation submitted to EMA, the Company received the assessment report including requests for supplementary information on December 15, 2022. Although the report stated that the benefits of rucaparib in the claimed indication could be considered meaningful with a manageable safety profile, it also stated that there are still some uncertainties that need to be resolved before a positive recommendation could be made. The report described the lack of mature OS data as the main limitation and contains a number of requests for supplementary information. As is often the case at this stage of an assessment procedure, the report stated that the overall benefit/risk of Rubraca in the front line maintenance setting is currently negative. The Company expects to provide the requested supplementary information to EMA in March 2023.

The Company is seeking to sell its assets through a court supervised sales process in the Cases. On December 11, 2022, the Company entered into a "stalking horse" purchase and assignment agreement with Novartis Innovative Therapies AG ("Novartis") to sell substantially all of its rights to its pipeline targeted radionuclide therapy clinical development program, FAP-2286, including the Company's in-licensing agreement with 3B Pharmaceuticals GmbH. The transaction is part of a sale process under Section 363 of title 11 of the United States Code (the "Bankruptcy Code") that is subject to approval by the Court and compliance with agreed upon and Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions. In accordance with the sale process under Section 363 of the Bankruptcy Code, notice of the proposed sale to Novartis has been given to third parties and competing bids are being solicited. The deadline to submit competing bids for the FAP-2286 assets has been set for March 7, 2023 by the Court in the bidding procedures order. The transaction is subject to a number of closing conditions, including among others, (i) the accuracy of representations and warranties of the parties; (ii) the entry into a transition services agreement mutually acceptable to the parties; (iii) material compliance with the obligations of the parties set forth in the purchase agreement, including achievement of certain milestones by the Company related to the Cases and the sales process on a timely basis; (iv) no Material Adverse Effect (as defined in the purchase agreement) having occurred to the transferred assets; and (v) payment of cure costs in respect of any assigned contract related to the FAP-2286 assets.

Separately, the Company is also actively engaged in discussions with a number of interested parties with respect to a potential sale of its Rubraca assets and business. That sale would also be subject to review and approval by the Court and compliance with Court-approved bidding procedures. The deadline to submit bids for the purchase of the Company's Rubraca assets and business has been set for March 21, 2023 by the Court in the bidding procedures order. The Company will manage the bidding process and evaluate the bids, in consultation with its advisors and other primary constituents and as overseen by the Court. There can be no assurances that any qualified or acceptable bids will be received or, even if received, the Company will be able to agree upon definitive terms with any such bidders and, even if a definitive agreement is entered into, there can be no assurances that it would be approved by the Court or that it would ultimately be consummated.

In connection with the sale process, the Debtors have filed notices with the Court (and have delivered notices to counterparties to the Debtors' contracts) detailing the Debtors' estimated amounts necessary to cure any defaults under the Company's executory contracts and unexpired leases that could potentially be assumed and assigned to the purchasers of the FAP-2286 and/or Rubraca assets.

Cautionary Statements Regarding Trading in the Company's Securities

The Company's securityholders are cautioned that trading in the Company's securities during the pendency of the Cases is highly speculative and poses substantial risks. Trading prices for the Company's securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Cases. The Company cannot be certain that holders of the Company's common stock will receive any payment or other distribution on account of those shares in the Cases given the expected sales proceeds (including the highly contingent nature of certain later milestone payments) and the amount of the Debtors' liabilities to more senior creditors. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

Cautionary Note Regarding Forward-Looking Statements

This Form 8-K includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein. Any forward-looking statements that we make in this Form 8-K speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 8-K or to reflect the occurrence of unanticipated events. The Company’s forward-looking statements in this Form 8-K include, but are not limited to, statements about the Company’s plans to sell its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code and the timing of such sales and ability to satisfy closing conditions; the Company’s intention to continue operations during the Chapter 11 case; the Company’s belief that the sale process will be in the best interest of the Company and its stakeholders; and other statements regarding the Company’s strategy and future operations, performance and prospects among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Chapter 11 filings on the Company’s liquidity and results of operations; changes in the Company’s ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations; the outcome and timing of the Chapter 11 process and any potential asset sale; the effect of the Chapter 11 filings and any potential asset sale on the Company’s relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the potential asset sale; uncertainty regarding obtaining Court approval of a sale of the Company’s assets or other conditions to the potential asset sale; and the timing or amount of any distributions, if any, to the Company’s stakeholders.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit	Description
99.1	Clovis Oncology, Inc., Monthly Operating Report, dated December 31, 2022.
99.2	Clovis Oncology Ireland Limited, Monthly Operating Report, dated December 31, 2022.
99.3	Clovis Oncology UK Limited, Monthly Operating Report, dated December 31, 2022.
104	The cover page from Clovis Oncology, Inc.'s Current Report on Form 8-K is formatted in iXBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 10, 2023

CLOVIS ONCOLOGY, INC.

By: /s/ Paul Gross

Name: Paul Gross

Title: Executive Vice President and General Counsel

UNITED STATES BANKRUPTCY COURT
 _____ DISTRICT OF Delaware _____

In Re. Clovis Oncology, Inc. § Case No. 22-11292
 _____ §
 Debtor(s) §
 _____ §
 _____ §
 _____ §
 _____ §

Lead Case No. 22-11292

Jointly Administered

Monthly Operating Report Chapter 11

Reporting Period Ended: 12/31/2022 Petition Date: 12/11/2022

Months Pending: 1 Industry Classification:

3	2	5	4
---	---	---	---

Reporting Method: Accrual Basis Cash Basis

Debtor's Full-Time Employees (current): 119

Debtor's Full-Time Employees (as of date of order for relief): 120

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- Statement of cash receipts and disbursements
- Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- Statement of operations (profit or loss statement)
- Accounts receivable aging
- Postpetition liabilities aging
- Statement of capital assets
- Schedule of payments to professionals
- Schedule of payments to insiders
- All bank statements and bank reconciliations for the reporting period
- Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Andrew S. Mordkoff
 Signature of Responsible Party
02/08/2023
 Date

Andrew S. Mordkoff
 Printed Name of Responsible Party
787 Seventh Avenue, New York, New York 10019-6099
 Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Part 1: Cash Receipts and Disbursements		Current Month	Cumulative
a.	Cash balance beginning of month	\$7,157,147	
b.	Total receipts (net of transfers between accounts)	\$32,842,049	\$32,842,049
c.	Total disbursements (net of transfers between accounts)	\$1,392,300	\$1,392,300
d.	Cash balance end of month (a+b-c)	\$38,606,896	
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$1,392,300	\$1,392,300
Part 2: Asset and Liability Status		Current Month	
<i>(Not generally applicable to Individual Debtors. See Instructions.)</i>			
a.	Accounts receivable (total net of allowance)	\$12,621,898	
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$0	
c.	Inventory (Book <input checked="" type="radio"/> Market <input type="radio"/> Other <input type="radio"/> (attach explanation))	\$96,207,143	
d.	Total current assets	\$184,984,565	
e.	Total assets	\$314,981,798	
f.	Postpetition payables (excluding taxes)	\$39,967,803	
g.	Postpetition payables past due (excluding taxes)	\$627,827	
h.	Postpetition taxes payable	\$0	
i.	Postpetition taxes past due	\$0	
j.	Total postpetition debt (f+h)	\$39,967,803	
k.	Prepetition secured debt	\$346,993,967	
l.	Prepetition priority debt	\$40,600	
m.	Prepetition unsecured debt	\$498,564,016	
n.	Total liabilities (debt) (j+k+l+m)	\$885,566,386	
o.	Ending equity/net worth (e-n)	\$-570,584,588	
Part 3: Assets Sold or Transferred		Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$0
b.	Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$0
Part 4: Income Statement (Statement of Operations)		Current Month	Cumulative
<i>(Not generally applicable to Individual Debtors. See Instructions.)</i>			
a.	Gross income/sales (net of returns and allowances)	\$7,446,976	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$2,148,027	
c.	Gross profit (a-b)	\$5,298,949	
d.	Selling expenses	\$-208,763	
e.	General and administrative expenses	\$11,669,979	
f.	Other expenses	\$647,299	
g.	Depreciation and/or amortization (not included in 4b)	\$0	
h.	Interest	\$120,268,051	
i.	Taxes (local, state, and federal)	\$72,018	
j.	Reorganization items	\$80,259	
k.	Profit (loss)	\$-133,461,703	\$-133,461,703

Part 5: Professional Fees and Expenses

		Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative	
a.	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
		Firm Name	Role			
		i				
		ii				
		iii				
		iv				
		v				
		vi				
		vii				
		viii				
		ix				
		x				
		xi				
		xii				
		xiii				
		xiv				
		xv				
		xvi				
		xvii				
		xviii				
		xix				
		xx				
		xxi				
		xxii				
		xxiii				
		xxiv				
		xxv				
		xxvi				
		xxvii				
		xxviii				
		xxix				
		xxx				
	xxxi					
	xxxii					
	xxxiii					
	xxxiv					
	xxxv					
	xxxvi					

xxxvii					
xxxvii					
xxxix					
xl					
xli					
xlii					
xliii					
xliv					
xlv					
xlvi					
xlvii					
xlviii					
xliv					
l					
li					
lii					
liii					
liv					
lv					
lvi					
lvii					
lviii					
lix					
lx					
lxi					
lxii					
lxiii					
lxiv					
lxv					
lxvi					
lxvii					
lxviii					
lxix					
lxx					
lxxi					
lxxii					
lxxiii					
lxxiv					
lxxv					
lxxvi					
lxxvii					
lxxvii					

Debtor's Name Clovis Oncology, Inc.

Case No. 22-11292

lxxix					
lxxx					
lxxxi					
lxxxii					
lxxxii					
lxxxiv					
lxxxv					
lxxxvi					
lxxxvi					
lxxxvi					
lxxxix					
xc					
xc					
xcii					
xciii					
xciv					
xcv					
xcvi					
xcvii					
xcviii					
xcix					
c					
ci					

		Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative	
b.	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
		Firm Name	Role			
	i					
	ii					
	iii					
	iv					
	v					
	vi					
	vii					
	viii					
	ix					
	x					
	xi					
	xii					
xiii						
xiv						

xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxvii						
lxxix						
lxxx						
lxxx						
lxxxii						
lxxxii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						

xcix						
c						
c.	All professional fees and expenses (debtor & committees)			\$0	\$0	\$0

Part 6: Postpetition Taxes	Current Month	Cumulative
a. Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b. Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c. Postpetition employer payroll taxes accrued	\$0	\$0
d. Postpetition employer payroll taxes paid	\$0	\$0
e. Postpetition property taxes paid	\$0	\$0
f. Postpetition other taxes accrued (local, state, and federal)	\$0	\$0
g. Postpetition other taxes paid (local, state, and federal)	\$0	\$0

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes No
- c. Were any payments made to or on behalf of insiders? Yes No
- d. Are you current on postpetition tax return filings? Yes No
- e. Are you current on postpetition estimated tax payments? Yes No
- f. Were all trust fund taxes remitted on a current basis? Yes No
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes No
- h. Were all payments made to or on behalf of professionals approved by the court? Yes No N/A
- i. Do you have:
 - Worker's compensation insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - Casualty/property insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - General liability insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes No
- k. Has a disclosure statement been filed with the court? Yes No
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes No

Part 8: Individual Chapter 11 Debtors (Only)

a. Gross income (receipts) from salary and wages	\$0
b. Gross income (receipts) from self-employment	\$0
c. Gross income from all other sources	\$0
d. Total income in the reporting period (a+b+c)	\$0
e. Payroll deductions	\$0
f. Self-employment related expenses	\$0
g. Living expenses	\$0
h. All other expenses	\$0
i. Total expenses in the reporting period (e+f+g+h)	\$0
j. Difference between total income and total expenses (d-i)	\$0
k. List the total amount of all postpetition debts that are past due	\$0
l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?	Yes <input type="radio"/> No <input checked="" type="radio"/>
m. If yes, have you made all Domestic Support Obligation payments?	Yes <input type="radio"/> No <input type="radio"/> N/A <input checked="" type="radio"/>

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Daniel W. Muehl


 Signature of Responsible Party
 Executive Vice President and Chief Financial Officer

 Title


Daniel W. Muehl

 Printed Name of Responsible Party
 02/08/2023


 Date




PageOnePartOne




PageOnePartTwo




PageTwoPartOne




PageTwoPartTwo




Bankruptcy1to50




Bankruptcy51to100




NonBankruptcy1to50



NonBankruptcy51to100



PageThree



PageFour

In re: Clovis Oncology, Inc.
Schedule of Cash Receipts and Disbursements

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Debtor	Third-Party Cash Disbursements
Clovis Oncology, Inc.	1,392,300
Clovis Oncology UK Limited	86,398
Clovis Oncology Ireland Limited	23,752
Total	1,502,450

Debtor	Third-Party Cash Receipts
Clovis Oncology, Inc.	32,739,902
Clovis Oncology UK Limited	25,957
Clovis Oncology Ireland Limited	-
Total	32,765,860

In re: Clovis Oncology, Inc.
Bank Account Information

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Debtor	Bank	Last 4 Digits	Description	Balance as of Month End (USD)
Clovis Oncology, Inc.	JP Morgan	9101	Lockbox Account	4,838,538
Clovis Oncology, Inc.	JP Morgan	8623	Operating Account	26,993,091
Clovis Oncology, Inc.	JP Morgan	9601	Operating Account	34
Clovis Oncology, Inc.	JP Morgan	9602	Operating Account	2,056
Clovis Oncology, Inc.	JP Morgan	3424	Operating Account	687
Clovis Oncology, Inc.	JP Morgan	8157	Investment Account	6,672,490
Clovis Oncology, Inc.	JP Morgan	2038	Investment Account	100,000
Clovis Oncology UK Limited	JP Morgan	4225	Lockbox Account	2,984,136
Clovis Oncology UK Limited	JP Morgan	2330	Operating Account	4,903,362
Clovis Oncology Ireland Limited	JP Morgan	0565	Lockbox Account	68,626
Clovis Oncology Ireland Limited	JP Morgan	1185	Operating Account	553,332
Sub Total - Bank Accounts				47,116,352
Total				47,116,352

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Assets			
Current Assets:			
Cash and Cash Equivalents	38,606,897	7,887,498	621,957
Trade Accounts Receivable, Net	12,621,898	5,802,510	4,609
Intero Receivables	21,953,479	551	7,283,042
Pre-Petition - Inter Company Debtor Receivables			
Inventories	96,207,143	-	13,247,702
Prepayments and Deposits	15,582,729	14,793	12,950
Other Assets - Current	12,417	2,735,563	26,392
IC Investment in Subsidiaries	2	229,143	-
Total Current Assets	184,984,565	16,670,057	21,196,653
Non-Current Assets:			
Property, Plant and Equipment, Net	481,414	136,605	-
Goodwill	63,074,218	-	-
Other Intangible Assets, Net	55,000,286	-	-
Other Assets - Non-current	11,441,315	262,827	34,195
Total Non-Current Assets	129,997,233	399,433	34,195
Total Assets	314,981,798	17,069,489	21,230,848
Liabilities			
Current Liabilities:			
DIP Financing	30,000,000	-	-
Trade Accounts Payable, Net	1,331,976	76,940	34,005
Intero Payables	(409,039)	754,943	18,362,246
Misc. Liabilities & Accrued Expenses	8,931,561	4,164,577	109,788
Accrued Taxes (Income, Payroll, etc.)	(17,614)	1,897,591	277,806
Lease Liability - Short-term	130,920	202,777	16,965
Other Notes Payable - Current	-	-	-
Total Current Liabilities	39,967,803	7,096,829	18,800,809
Non-Current Liabilities			
Lease Liability - Long-term	0	0	15,019
Total Non-Current Liabilities	0	0	15,019
Liabilities Subject to Compromise	845,598,583	7,294,983	74,315
Total Liabilities	885,566,386	14,391,812	18,890,144
Equity			
Common Stock	145,068	2	141
Additional Paid in Capital	2,691,517,358	-	-
Accumulated Other Comprehensive Loss	(41,905,090)	(459,281)	86,265
Accumulated Deficit	(3,220,341,925)	3,136,957	2,254,299
Total Equity	(570,584,588)	2,677,677	2,340,704
Total Liabilities and Equity	314,981,798	17,069,489	21,230,848

Notes:

1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: Clovis Oncology, Inc.

Unaudited Statement of Operations for the month of December 2022

Lead Case No: 22-11292 (JKS)

Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Total Revenue	7,446,976	445,325	1,916,352
Operating Expenses:			
Cost of Goods Sold	804,825	565,937	1,057,856
Royalty Expense	1,343,202	-	-
Research and Development	3,632,718	-	-
General and Administrative	11,669,979	586,405	13,875
Selling Expenses	(208,763)	66,291	-
Operating Taxes	72,018	-	-
Other Operating Expenses	514,810	-	-
Total Operating Expenses	17,828,790	1,218,633	1,071,732
Total Operating Profit (Loss)	(10,381,814)	(773,308)	844,620
Other Income and Expenses:			
Interest Income	37,853	-	-
Gain/Loss from Sale of Assets	(3,153,757)	(770,843)	-
Interest Expense	120,230,198	1,861	11,935
Foreign Currency Translation Adjustments	(379,321)	36,970	(275,635)
Gain/Loss on Available-For-Sale Securities	32,848	-	-
Reorganization Costs	80,259	(113,255)	-
Income Tax Expense	-	(251,313)	397,526
Net Other Income	(123,079,889)	(445,106)	(133,825)
Net Income	(133,461,703)	(1,218,414)	710,795

Notes:

1) The activity reported above represents the full month of December.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

In re: Clovis Oncology, Inc.
Accounts Receivable Reconciliation and Aging

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Clovis Oncology, Inc.

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	12,801,690	330,030	-	-	13,131,720
Less: Prompt Pay Discounts & Returns	(492,373)	-	-	-	(492,373)
Less: Allowance for Bad Debts	(15,799)	(1,650)	-	-	(17,449)
Net Accounts Receivable	12,293,518	328,380	-	-	12,621,898

Clovis Oncology UK Limited

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	5,819,970	-	-	-	5,819,970
Less: Allowance for Bad Debts	(17,460)	-	-	-	(17,460)
Net Accounts Receivable	5,802,510	-	-	-	5,802,510

Clovis Oncology Ireland Limited

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	4,632	-	-	-	4,632
Less: Allowance for Bad Debts	(23)	-	-	-	(23)
Net Accounts Receivable	4,609	-	-	-	4,609

In re: Clovis Oncology, Inc.
Post-Petition Accounts Payable Aging

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Debtor	Total	Current	0-30 Days	31-60 Days	61-90 Days	91+ Days
Clovis Oncology, Inc	1,332,293	704,466	353,408	24,587	7,163	242,669
Clovis Oncology UK Limited	76,940	45,240	31,728	(28)	-	-
Clovis Oncology Ireland Limited	34,005	34,005	-	-	-	-
Net Accounts Payable	1,443,238	783,711	385,136	24,559	7,163	242,669

Notes:

1) While the Debtors' AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case.

In re: Clovis Oncology, Inc.
Schedule of Capital Assets

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Net Book Value			
Computer Equipment	159,402	107,204	-
Furniture and Fixtures	246,621	4,267	-
Lab Equipment	5,460	-	-
Leasehold Improvements	47,600	-	-
Licensed Software	-	-	-
Manufacturing Equipment	5,512	-	-
Office Equipment	9,929	1,389	-
Trade Booth	-	-	-
Net Book Value	474,524	112,859	-

In re: Clovis Oncology, Inc.
Schedule of Payments to Insiders

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Payments to Insiders	145,763	-	-

The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of December 11 through December 31, 2022. With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period.

/s/ Daniel W. Muehl
Signature of Authorized Individual

02/08/2023
Date

Daniel W. Muehl
Printed Name of Authorized Individual

Executive Vice President and Chief Financial Officer
Title of Authorized Individual

Notes:

1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors' Statements of Financial Affairs. The amount listed includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements.

In re: Clovis Oncology, Inc.
Status of Post-Petition Taxes

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute.

/s/ Daniel W. Muehl
Signature of Authorized Individual

Daniel W. Muehl
Printed Name of Authorized Individual

02/08/2023
Date

Executive Vice President and Chief Financial Officer
Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT
 _____ DISTRICT OF Delaware _____

In Re. Clovis Oncology Ireland Limited _____ Debtor(s)	§ § § §	Case No. <u>22-11294</u> Lead Case No. <u>22-11292</u> <input checked="" type="checkbox"/> Jointly Administered
--	------------------	---

Monthly Operating Report Chapter 11

Reporting Period Ended: <u>12/31/2022</u>	Petition Date: <u>12/11/2022</u>				
Months Pending: <u>1</u>	Industry Classification: <table border="1" style="display: inline-table; border-collapse: collapse;"><tr><td style="width: 20px; text-align: center;">3</td><td style="width: 20px; text-align: center;">2</td><td style="width: 20px; text-align: center;">5</td><td style="width: 20px; text-align: center;">4</td></tr></table>	3	2	5	4
3	2	5	4		
Reporting Method: Accrual Basis <input checked="" type="radio"/> Cash Basis <input type="radio"/>					
Debtor's Full-Time Employees (current):	<u>1</u>				
Debtor's Full-Time Employees (as of date of order for relief):	<u>1</u>				

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- Statement of cash receipts and disbursements
- Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- Statement of operations (profit or loss statement)
- Accounts receivable aging
- Postpetition liabilities aging
- Statement of capital assets
- Schedule of payments to professionals
- Schedule of payments to insiders
- All bank statements and bank reconciliations for the reporting period
- Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Andrew S. Mordkoff
 Signature of Responsible Party

02/08/2023
 Date

Andrew S. Mordkoff
 Printed Name of Responsible Party

787 Seventh Avenue, New York, New York 10019-6099
 Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Part 1: Cash Receipts and Disbursements	Current Month	Cumulative
a. Cash balance beginning of month	\$631,500	
b. Total receipts (net of transfers between accounts)	\$14,210	\$14,210
c. Total disbursements (net of transfers between accounts)	\$23,752	\$23,752
d. Cash balance end of month (a+b-c)	\$621,958	
e. Disbursements made by third party for the benefit of the estate	\$0	\$0
f. Total disbursements for quarterly fee calculation (c+e)	\$23,752	\$23,752

Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.)	Current Month
a. Accounts receivable (total net of allowance)	\$4,609
b. Accounts receivable over 90 days outstanding (net of allowance)	\$0
c. Inventory (Book <input checked="" type="radio"/> Market <input type="radio"/> Other <input type="radio"/> (attach explanation))	\$13,247,702
d. Total current assets	\$21,196,653
e. Total assets	\$21,230,848
f. Postpetition payables (excluding taxes)	\$18,815,829
g. Postpetition payables past due (excluding taxes)	\$0
h. Postpetition taxes payable	\$0
i. Postpetition taxes past due	\$0
j. Total postpetition debt (f+h)	\$18,815,829
k. Prepetition secured debt	\$0
l. Prepetition priority debt	\$0
m. Prepetition unsecured debt	\$74,315
n. Total liabilities (debt) (j+k+l+m)	\$18,890,144
o. Ending equity/net worth (e-n)	\$2,340,704

Part 3: Assets Sold or Transferred	Current Month	Cumulative
a. Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$0
b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$0

Part 4: Income Statement (Statement of Operations) (Not generally applicable to Individual Debtors. See Instructions.)	Current Month	Cumulative
a. Gross income/sales (net of returns and allowances)	\$1,916,352	
b. Cost of goods sold (inclusive of depreciation, if applicable)	\$1,057,856	
c. Gross profit (a-b)	\$858,496	
d. Selling expenses	\$0	
e. General and administrative expenses	\$13,875	
f. Other expenses	\$-275,635	
g. Depreciation and/or amortization (not included in 4b)	\$0	
h. Interest	\$11,935	
i. Taxes (local, state, and federal)	\$397,526	
j. Reorganization items	\$0	
k. Profit (loss)	\$710,795	\$710,795

Part 5: Professional Fees and Expenses

		Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
a.	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>				
	<i>Itemized Breakdown by Firm</i>				
		Firm Name	Role		
	i				
	ii				
	iii				
	iv				
	v				
	vi				
	vii				
	viii				
	ix				
	x				
	xi				
	xii				
	xiii				
	xiv				
	xv				
	xvi				
	xvii				
	xviii				
	xix				
	xx				
	xxi				
	xxii				
	xxiii				
	xxiv				
	xxv				
	xxvi				
	xxvii				
	xxviii				
	xxix				
	xxx				
	xxxi				
	xxxii				
	xxxiii				
	xxxiv				
	xxxv				
	xxxvi				

xxxvii						
xxxvii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxvii						

lxxix					
lxxx					
lxxxi					
lxxxii					
lxxxii					
lxxxiv					
lxxxv					
lxxxvi					
lxxxvi					
lxxxvi					
lxxxix					
xc					
xc					
xcii					
xciii					
xciv					
xcv					
xevi					
xcvii					
xcviii					
xcix					
c					
ci					

		Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative	
b.	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
		Firm Name	Role			
	i					
	ii					
	iii					
	iv					
	v					
	vi					
	vii					
	viii					
	ix					
	x					
	xi					
	xii					
xiii						
xiv						

xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvii						
lxxxviii						
lxxxix						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						

xcix						
c						
c.	All professional fees and expenses (debtor & committees)			\$0	\$0	\$0

Part 6: Postpetition Taxes	Current Month	Cumulative
a. Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b. Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c. Postpetition employer payroll taxes accrued	\$0	\$0
d. Postpetition employer payroll taxes paid	\$0	\$0
e. Postpetition property taxes paid	\$0	\$0
f. Postpetition other taxes accrued (local, state, and federal)	\$0	\$0
g. Postpetition other taxes paid (local, state, and federal)	\$0	\$0

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes No
- c. Were any payments made to or on behalf of insiders? Yes No
- d. Are you current on postpetition tax return filings? Yes No
- e. Are you current on postpetition estimated tax payments? Yes No
- f. Were all trust fund taxes remitted on a current basis? Yes No
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes No
- h. Were all payments made to or on behalf of professionals approved by the court? Yes No N/A
- i. Do you have:
 - Worker's compensation insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - Casualty/property insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - General liability insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes No
- k. Has a disclosure statement been filed with the court? Yes No
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes No

Part 8: Individual Chapter 11 Debtors (Only)

- | | |
|--|---|
| a. Gross income (receipts) from salary and wages | \$0 |
| b. Gross income (receipts) from self-employment | \$0 |
| c. Gross income from all other sources | \$0 |
| d. Total income in the reporting period (a+b+c) | \$0 |
| e. Payroll deductions | \$0 |
| f. Self-employment related expenses | \$0 |
| g. Living expenses | \$0 |
| h. All other expenses | \$0 |
| i. Total expenses in the reporting period (e+f+g+h) | \$0 |
| j. Difference between total income and total expenses (d-i) | \$0 |
| k. List the total amount of all postpetition debts that are past due | \$0 |
| l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)? | Yes <input type="radio"/> No <input checked="" type="radio"/> |
| m. If yes, have you made all Domestic Support Obligation payments? | Yes <input type="radio"/> No <input type="radio"/> N/A <input checked="" type="radio"/> |

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Daniel W. Muehl

Signature of Responsible Party

Executive Vice President and Chief Financial Officer


Title

Daniel W. Muehl


Printed Name of Responsible Party

02/08/2023


Date




PageOnePartOne




PageOnePartTwo




PageTwoPartOne




PageTwoPartTwo




Bankruptcy1to50




Bankruptcy51to100




NonBankruptcy1to50



NonBankruptcy51to100



PageThree



PageFour

In re: Clovis Oncology, Inc.
Schedule of Cash Receipts and Disbursements

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Debtor	Third-Party Cash Disbursements
Clovis Oncology, Inc.	1,392,300
Clovis Oncology UK Limited	86,398
Clovis Oncology Ireland Limited	23,752
Total	1,502,450

Debtor	Third-Party Cash Receipts
Clovis Oncology, Inc.	32,739,902
Clovis Oncology UK Limited	25,957
Clovis Oncology Ireland Limited	-
Total	32,765,860

Debtor	Bank	Last 4 Digits	Description	Balance as of Month End (USD)
Clovis Oncology, Inc.	JP Morgan	9101	Lockbox Account	4,838,538
Clovis Oncology, Inc.	JP Morgan	8623	Operating Account	26,993,091
Clovis Oncology, Inc.	JP Morgan	9601	Operating Account	34
Clovis Oncology, Inc.	JP Morgan	9602	Operating Account	2,056
Clovis Oncology, Inc.	JP Morgan	3424	Operating Account	687
Clovis Oncology, Inc.	JP Morgan	8157	Investment Account	6,672,490
Clovis Oncology, Inc.	JP Morgan	2038	Investment Account	100,000
Clovis Oncology UK Limited	JP Morgan	4225	Lockbox Account	2,984,136
Clovis Oncology UK Limited	JP Morgan	2330	Operating Account	4,903,362
Clovis Oncology Ireland Limited	JP Morgan	0565	Lockbox Account	68,626
Clovis Oncology Ireland Limited	JP Morgan	1185	Operating Account	553,332
Sub Total - Bank Accounts				47,116,352
Total				47,116,352

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Assets			
Current Assets:			
Cash and Cash Equivalents	38,606,897	7,887,498	621,957
Trade Accounts Receivable, Net	12,621,898	5,802,510	4,609
Intero Receivables	21,953,479	551	7,283,042
Pre-Petition - Inter Company Debtor Receivables			
Inventories	96,207,143	-	13,247,702
Prepayments and Deposits	15,582,729	14,793	12,950
Other Assets - Current	12,417	2,735,563	26,392
IC Investment in Subsidiaries	2	229,143	-
Total Current Assets	184,984,565	16,670,057	21,196,653
Non-Current Assets:			
Property, Plant and Equipment, Net	481,414	136,605	-
Goodwill	63,074,218	-	-
Other Intangible Assets, Net	55,000,286	-	-
Other Assets - Non-current	11,441,315	262,827	34,195
Total Non-Current Assets	129,997,233	399,433	34,195
Total Assets	314,981,798	17,069,489	21,230,848
Liabilities			
Current Liabilities:			
DIP Financing	30,000,000	-	-
Trade Accounts Payable, Net	1,331,976	76,940	34,005
Intero Payables	(409,039)	754,943	18,362,246
Misc. Liabilities & Accrued Expenses	8,931,561	4,164,577	109,788
Accrued Taxes (Income, Payroll, etc.)	(17,614)	1,897,591	277,806
Lease Liability - Short-term	130,920	202,777	16,965
Other Notes Payable - Current	-	-	-
Total Current Liabilities	39,967,803	7,096,829	18,800,809
Non-Current Liabilities			
Lease Liability - Long-term	0	0	15,019
Total Non-Current Liabilities	0	0	15,019
Liabilities Subject to Compromise	845,598,583	7,294,983	74,315
Total Liabilities	885,566,386	14,391,812	18,890,144
Equity			
Common Stock	145,068	2	141
Additional Paid in Capital	2,691,517,358	-	-
Accumulated Other Comprehensive Loss	(41,905,090)	(459,281)	86,265
Accumulated Deficit	(3,220,341,925)	3,136,957	2,254,299
Total Equity	(570,584,588)	2,677,677	2,340,704
Total Liabilities and Equity	314,981,798	17,069,489	21,230,848

Notes:

1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: Clovis Oncology, Inc.

Unaudited Statement of Operations for the month of December 2022

Lead Case No: 22-11292 (JKS)

Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Total Revenue	7,446,976	445,325	1,916,352
Operating Expenses:			
Cost of Goods Sold	804,825	565,937	1,057,856
Royalty Expense	1,343,202	-	-
Research and Development	3,632,718	-	-
General and Administrative	11,669,979	586,405	13,875
Selling Expenses	(208,763)	66,291	-
Operating Taxes	72,018	-	-
Other Operating Expenses	514,810	-	-
Total Operating Expenses	17,828,790	1,218,633	1,071,732
Total Operating Profit (Loss)	(10,381,814)	(773,308)	844,620
Other Income and Expenses:			
Interest Income	37,853	-	-
Gain/Loss from Sale of Assets	(3,153,757)	(770,843)	-
Interest Expense	120,230,198	1,861	11,935
Foreign Currency Translation Adjustments	(379,321)	36,970	(275,635)
Gain/Loss on Available-For-Sale Securities	32,848	-	-
Reorganization Costs	80,259	(113,255)	-
Income Tax Expense	-	(251,313)	397,526
Net Other Income	(123,079,889)	(445,106)	(133,825)
Net Income	(133,461,703)	(1,218,414)	710,795

Notes:

1) The activity reported above represents the full month of December.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

In re: Clovis Oncology, Inc.
Accounts Receivable Reconciliation and Aging

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Clovis Oncology, Inc.

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	12,801,690	330,030	-	-	13,131,720
Less: Prompt Pay Discounts & Returns	(492,373)	-	-	-	(492,373)
Less: Allowance for Bad Debts	(15,799)	(1,650)	-	-	(17,449)
Net Accounts Receivable	12,293,518	328,380	-	-	12,621,898

Clovis Oncology UK Limited

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	5,819,970	-	-	-	5,819,970
Less: Allowance for Bad Debts	(17,460)	-	-	-	(17,460)
Net Accounts Receivable	5,802,510	-	-	-	5,802,510

Clovis Oncology Ireland Limited

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	4,632	-	-	-	4,632
Less: Allowance for Bad Debts	(23)	-	-	-	(23)
Net Accounts Receivable	4,609	-	-	-	4,609

In re: Clovis Oncology, Inc.
Post-Petition Accounts Payable Aging

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Debtor	Total	Current	0-30 Days	31-60 Days	61-90 Days	91+ Days
Clovis Oncology, Inc	1,332,293	704,466	353,408	24,587	7,163	242,669
Clovis Oncology UK Limited	76,940	45,240	31,728	(28)	-	-
Clovis Oncology Ireland Limited	34,005	34,005	-	-	-	-
Net Accounts Payable	1,443,238	783,711	385,136	24,559	7,163	242,669

Notes:

1) While the Debtors' AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case.

In re: Clovis Oncology, Inc.
Schedule of Capital Assets

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Net Book Value			
Computer Equipment	159,402	107,204	-
Furniture and Fixtures	246,621	4,267	-
Lab Equipment	5,460	-	-
Leasehold Improvements	47,600	-	-
Licensed Software	-	-	-
Manufacturing Equipment	5,512	-	-
Office Equipment	9,929	1,389	-
Trade Booth	-	-	-
Net Book Value	474,524	112,859	-

In re: Clovis Oncology, Inc.
Schedule of Payments to Insiders

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Payments to Insiders	145,763	-	-

The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of December 11 through December 31, 2022. With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period.

/s/ Daniel W. Muehl
Signature of Authorized Individual

02/08/2023
Date

Daniel W. Muehl
Printed Name of Authorized Individual

Executive Vice President and Chief Financial Officer
Title of Authorized Individual

Notes:

1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors' Statements of Financial Affairs. The amount listed includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements.

In re: Clovis Oncology, Inc.
Status of Post-Petition Taxes

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute.

/s/ Daniel W. Muehl
Signature of Authorized Individual

Daniel W. Muehl
Printed Name of Authorized Individual

02/08/2023
Date

Executive Vice President and Chief Financial Officer
Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT
 _____ DISTRICT OF Delaware _____

In Re. Clovis Oncology UK Limited	§	Case No. <u>22-11293</u>
	§	
Debtor(s)	§	Lead Case No. <u>22-11292</u>
	§	<input checked="" type="checkbox"/> Jointly Administered

Monthly Operating Report Chapter 11

Reporting Period Ended: <u>12/31/2022</u>	Petition Date: <u>12/11/2022</u>				
Months Pending: <u>1</u>	Industry Classification: <table border="1" style="display: inline-table; border-collapse: collapse;"><tr><td style="width: 20px; text-align: center;">3</td><td style="width: 20px; text-align: center;">2</td><td style="width: 20px; text-align: center;">5</td><td style="width: 20px; text-align: center;">4</td></tr></table>	3	2	5	4
3	2	5	4		
Reporting Method: Accrual Basis <input checked="" type="radio"/> Cash Basis <input type="radio"/>					
Debtor's Full-Time Employees (current):	<u>49</u>				
Debtor's Full-Time Employees (as of date of order for relief):	<u>49</u>				

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- Statement of cash receipts and disbursements
- Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- Statement of operations (profit or loss statement)
- Accounts receivable aging
- Postpetition liabilities aging
- Statement of capital assets
- Schedule of payments to professionals
- Schedule of payments to insiders
- All bank statements and bank reconciliations for the reporting period
- Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Andrew S. Mordkoff
 Signature of Responsible Party
02/08/2023
 Date

Andrew S. Mordkoff
 Printed Name of Responsible Party
787 Seventh Avenue, New York, New York 10019-6099
 Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Part 1: Cash Receipts and Disbursements		Current Month	Cumulative
a.	Cash balance beginning of month	\$8,077,306	
b.	Total receipts (net of transfers between accounts)	\$-103,410	\$-103,410
c.	Total disbursements (net of transfers between accounts)	\$86,398	\$86,398
d.	Cash balance end of month (a+b-c)	\$7,887,498	
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$86,398	\$86,398
Part 2: Asset and Liability Status		Current Month	
<i>(Not generally applicable to Individual Debtors. See Instructions.)</i>			
a.	Accounts receivable (total net of allowance)	\$5,802,510	
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$0	
c.	Inventory (Book <input checked="" type="radio"/> Market <input type="radio"/> Other <input type="radio"/> (attach explanation))	\$0	
d.	Total current assets	\$16,670,057	
e.	Total assets	\$17,069,489	
f.	Postpetition payables (excluding taxes)	\$7,096,829	
g.	Postpetition payables past due (excluding taxes)	\$31,700	
h.	Postpetition taxes payable	\$0	
i.	Postpetition taxes past due	\$0	
j.	Total postpetition debt (f+h)	\$7,096,829	
k.	Prepetition secured debt	\$0	
l.	Prepetition priority debt	\$0	
m.	Prepetition unsecured debt	\$7,294,983	
n.	Total liabilities (debt) (j+k+l+m)	\$14,391,812	
o.	Ending equity/net worth (e-n)	\$2,677,677	
Part 3: Assets Sold or Transferred		Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$0
b.	Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$0
Part 4: Income Statement (Statement of Operations)		Current Month	Cumulative
<i>(Not generally applicable to Individual Debtors. See Instructions.)</i>			
a.	Gross income/sales (net of returns and allowances)	\$445,325	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$565,937	
c.	Gross profit (a-b)	\$-120,612	
d.	Selling expenses	\$66,291	
e.	General and administrative expenses	\$586,405	
f.	Other expenses	\$-733,873	
g.	Depreciation and/or amortization (not included in 4b)	\$0	
h.	Interest	\$1,861	
i.	Taxes (local, state, and federal)	\$-251,313	
j.	Reorganization items	\$-113,255	
k.	Profit (loss)	\$-1,218,414	\$-1,218,414

Part 5: Professional Fees and Expenses

		Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
a.	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>				
	<i>Itemized Breakdown by Firm</i>				
		Firm Name	Role		
	i				
	ii				
	iii				
	iv				
	v				
	vi				
	vii				
	viii				
	ix				
	x				
	xi				
	xii				
	xiii				
	xiv				
	xv				
	xvi				
	xvii				
	xviii				
	xix				
	xx				
	xxi				
	xxii				
	xxiii				
	xxiv				
	xxv				
	xxvi				
	xxvii				
	xxviii				
	xxix				
	xxx				
	xxxi				
	xxxii				
	xxxiii				
	xxxiv				
	xxxv				
	xxxvi				

xxxvii						
xxxvii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxvii						

lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative	
b.	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>						
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
xiii							
xiv							

xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxvii						
lxxix						
lxxx						
lxxxii						
lxxxii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xcii						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						

Debtor's Name Clovis Oncology UK Limited

Case No. 22-11293

	xcix					
	c					
c.	All professional fees and expenses (debtor & committees)			\$0	\$0	\$0

Part 6: Postpetition Taxes	Current Month	Cumulative
a. Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b. Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c. Postpetition employer payroll taxes accrued	\$0	\$0
d. Postpetition employer payroll taxes paid	\$0	\$0
e. Postpetition property taxes paid	\$0	\$0
f. Postpetition other taxes accrued (local, state, and federal)	\$0	\$0
g. Postpetition other taxes paid (local, state, and federal)	\$0	\$0

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes No
- c. Were any payments made to or on behalf of insiders? Yes No
- d. Are you current on postpetition tax return filings? Yes No
- e. Are you current on postpetition estimated tax payments? Yes No
- f. Were all trust fund taxes remitted on a current basis? Yes No
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes No
- h. Were all payments made to or on behalf of professionals approved by the court? Yes No N/A
- i. Do you have:
 - Worker's compensation insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - Casualty/property insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - General liability insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes No
- k. Has a disclosure statement been filed with the court? Yes No
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes No

Part 8: Individual Chapter 11 Debtors (Only)

a. Gross income (receipts) from salary and wages	_____	\$0
b. Gross income (receipts) from self-employment	_____	\$0
c. Gross income from all other sources	_____	\$0
d. Total income in the reporting period (a+b+c)	_____	\$0
e. Payroll deductions	_____	\$0
f. Self-employment related expenses	_____	\$0
g. Living expenses	_____	\$0
h. All other expenses	_____	\$0
i. Total expenses in the reporting period (e+f+g+h)	_____	\$0
j. Difference between total income and total expenses (d-i)	_____	\$0
k. List the total amount of all postpetition debts that are past due	_____	\$0
l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?	Yes <input type="radio"/> No <input checked="" type="radio"/>	
m. If yes, have you made all Domestic Support Obligation payments?	Yes <input type="radio"/> No <input type="radio"/> N/A <input checked="" type="radio"/>	


Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).


I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Daniel W. Muehl
Signature of Responsible Party
Executive Vice President and Chief Financial Officer
Title


Daniel W. Muehl
Printed Name of Responsible Party
02/08/2023
Date




PageOnePartOne




PageOnePartTwo




PageTwoPartOne




PageTwoPartTwo




Bankruptcy1to50




Bankruptcy51to100




NonBankruptcy1to50



NonBankruptcy51to100



PageThree



PageFour

In re: Clovis Oncology, Inc.
Schedule of Cash Receipts and Disbursements

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Debtor	Third-Party Cash Disbursements
Clovis Oncology, Inc.	1,392,300
Clovis Oncology UK Limited	86,398
Clovis Oncology Ireland Limited	23,752
Total	1,502,450

Debtor	Third-Party Cash Receipts
Clovis Oncology, Inc.	32,739,902
Clovis Oncology UK Limited	25,957
Clovis Oncology Ireland Limited	-
Total	32,765,860

Debtor	Bank	Last 4 Digits	Description	Balance as of Month End (USD)
Clovis Oncology, Inc.	JP Morgan	9101	Lockbox Account	4,838,538
Clovis Oncology, Inc.	JP Morgan	8623	Operating Account	26,993,091
Clovis Oncology, Inc.	JP Morgan	9601	Operating Account	34
Clovis Oncology, Inc.	JP Morgan	9602	Operating Account	2,056
Clovis Oncology, Inc.	JP Morgan	3424	Operating Account	687
Clovis Oncology, Inc.	JP Morgan	8157	Investment Account	6,672,490
Clovis Oncology, Inc.	JP Morgan	2038	Investment Account	100,000
Clovis Oncology UK Limited	JP Morgan	4225	Lockbox Account	2,984,136
Clovis Oncology UK Limited	JP Morgan	2330	Operating Account	4,903,362
Clovis Oncology Ireland Limited	JP Morgan	0565	Lockbox Account	68,626
Clovis Oncology Ireland Limited	JP Morgan	1185	Operating Account	553,332
Sub Total - Bank Accounts				47,116,352
Total				47,116,352

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Assets			
Current Assets:			
Cash and Cash Equivalents	38,606,897	7,887,498	621,957
Trade Accounts Receivable, Net	12,621,898	5,802,510	4,609
Intero Receivables	21,953,479	551	7,283,042
Pre-Petition - Inter Company Debtor Receivables			
Inventories	96,207,143	-	13,247,702
Prepayments and Deposits	15,582,729	14,793	12,950
Other Assets - Current	12,417	2,735,563	26,392
IC Investment in Subsidiaries	2	229,143	-
Total Current Assets	184,984,565	16,670,057	21,196,653
Non-Current Assets:			
Property, Plant and Equipment, Net	481,414	136,605	-
Goodwill	63,074,218	-	-
Other Intangible Assets, Net	55,000,286	-	-
Other Assets - Non-current	11,441,315	262,827	34,195
Total Non-Current Assets	129,997,233	399,433	34,195
Total Assets	314,981,798	17,069,489	21,230,848
Liabilities			
Current Liabilities:			
DIP Financing	30,000,000	-	-
Trade Accounts Payable, Net	1,331,976	76,940	34,005
Intero Payables	(409,039)	754,943	18,362,246
Misc. Liabilities & Accrued Expenses	8,931,561	4,164,577	109,788
Accrued Taxes (Income, Payroll, etc.)	(17,614)	1,897,591	277,806
Lease Liability - Short-term	130,920	202,777	16,965
Other Notes Payable - Current	-	-	-
Total Current Liabilities	39,967,803	7,096,829	18,800,809
Non-Current Liabilities			
Lease Liability - Long-term	0	0	15,019
Total Non-Current Liabilities	0	0	15,019
Liabilities Subject to Compromise	845,598,583	7,294,983	74,315
Total Liabilities	885,566,386	14,391,812	18,890,144
Equity			
Common Stock	145,068	2	141
Additional Paid in Capital	2,691,517,358	-	-
Accumulated Other Comprehensive Loss	(41,905,090)	(459,281)	86,265
Accumulated Deficit	(3,220,341,925)	3,136,957	2,254,299
Total Equity	(570,584,588)	2,677,677	2,340,704
Total Liabilities and Equity	314,981,798	17,069,489	21,230,848

Notes:

1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: Clovis Oncology, Inc.

Unaudited Statement of Operations for the month of December 2022

Lead Case No: 22-11292 (JKS)

Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Total Revenue	7,446,976	445,325	1,916,352
Operating Expenses:			
Cost of Goods Sold	804,825	565,937	1,057,856
Royalty Expense	1,343,202	-	-
Research and Development	3,632,718	-	-
General and Administrative	11,669,979	586,405	13,875
Selling Expenses	(208,763)	66,291	-
Operating Taxes	72,018	-	-
Other Operating Expenses	514,810	-	-
Total Operating Expenses	17,828,790	1,218,633	1,071,732
Total Operating Profit (Loss)	(10,381,814)	(773,308)	844,620
Other Income and Expenses:			
Interest Income	37,853	-	-
Gain/Loss from Sale of Assets	(3,153,757)	(770,843)	-
Interest Expense	120,230,198	1,861	11,935
Foreign Currency Translation Adjustments	(379,321)	36,970	(275,635)
Gain/Loss on Available-For-Sale Securities	32,848	-	-
Reorganization Costs	80,259	(113,255)	-
Income Tax Expense	-	(251,313)	397,526
Net Other Income	(123,079,889)	(445,106)	(133,825)
Net Income	(133,461,703)	(1,218,414)	710,795

Notes:

1) The activity reported above represents the full month of December.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

Clovis Oncology, Inc.

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	12,801,690	330,030	-	-	13,131,720
Less: Prompt Pay Discounts & Returns	(492,373)	-	-	-	(492,373)
Less: Allowance for Bad Debts	(15,799)	(1,650)	-	-	(17,449)
Net Accounts Receivable	12,293,518	328,380	-	-	12,621,898

Clovis Oncology UK Limited

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	5,819,970	-	-	-	5,819,970
Less: Allowance for Bad Debts	(17,460)	-	-	-	(17,460)
Net Accounts Receivable	5,802,510	-	-	-	5,802,510

Clovis Oncology Ireland Limited

Accounts Receivable Aging	0-30 Days	31-60 Days	61-90 Days	91+ Days	Total
Trade Accounts Receivable	4,632	-	-	-	4,632
Less: Allowance for Bad Debts	(23)	-	-	-	(23)
Net Accounts Receivable	4,609	-	-	-	4,609

In re: Clovis Oncology, Inc.
Post-Petition Accounts Payable Aging

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

Debtor	Total	Current	0-30 Days	31-60 Days	61-90 Days	91+ Days
Clovis Oncology, Inc	1,332,293	704,466	353,408	24,587	7,163	242,669
Clovis Oncology UK Limited	76,940	45,240	31,728	(28)	-	-
Clovis Oncology Ireland Limited	34,005	34,005	-	-	-	-
Net Accounts Payable	1,443,238	783,711	385,136	24,559	7,163	242,669

Notes:

1) While the Debtors' AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case.

In re: Clovis Oncology, Inc.
Schedule of Capital Assets

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Net Book Value			
Computer Equipment	159,402	107,204	-
Furniture and Fixtures	246,621	4,267	-
Lab Equipment	5,460	-	-
Leasehold Improvements	47,600	-	-
Licensed Software	-	-	-
Manufacturing Equipment	5,512	-	-
Office Equipment	9,929	1,389	-
Trade Booth	-	-	-
Net Book Value	474,524	112,859	-

In re: Clovis Oncology, Inc.
Schedule of Payments to Insiders

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

<i>USD Actuals</i>	Clovis Oncology, Inc.	Clovis Oncology UK Limited	Clovis Oncology Ireland Limited
Payments to Insiders	145,763	-	-

The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of December 11 through December 31, 2022. With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period.

/s/ Daniel W. Muehl
Signature of Authorized Individual

02/08/2023
Date

Daniel W. Muehl
Printed Name of Authorized Individual

Executive Vice President and Chief Financial Officer
Title of Authorized Individual

Notes:

1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors' Statements of Financial Affairs. The amount listed includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements.

In re: Clovis Oncology, Inc.
Status of Post-Petition Taxes

Lead Case No: 22-11292 (JKS)
Reporting Period: Dec 11 - Dec 31, 2022

The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute.

/s/ Daniel W. Muehl
Signature of Authorized Individual

Daniel W. Muehl
Printed Name of Authorized Individual

02/08/2023
Date

Executive Vice President and Chief Financial Officer
Title of Authorized Individual